CCL2 and malignant colon neoplasm: DCIS.com cells exhibit PI3K mutations that enhance AKT activity.52 In colon cancer, AKT/GSK3B stabilizes B-catenin and positively regulates CCR2 and MET activity.53,54 As such, PI3K mutations could indirectly affect CCL2 and HGF signaling in DCIS.com cells.